This bill proposes to amend the Public Health Service Act by adding a new title focused on "Chemical Abortion Risk Awareness." It defines "chemical abortion" as the use of abortion-inducing drugs to cause the death of an unborn child, specifically excluding treatments for ectopic or molar pregnancies and miscarriages. The legislation applies to any chemical abortion provider who receives federal funds or works for an entity that does, aiming to ensure women are comprehensively informed about the procedure's risks. Under the bill, these providers must, at least 24 hours before a chemical abortion, provide the woman with both electronic and paper copies of the full FDA-approved product label for each drug, with "Warnings and Precautions" sections highlighted. They are also required to read these highlighted sections aloud to the woman and obtain her written confirmation that these steps were completed. Failure to comply can result in the Secretary withholding federal funding from the provider or their associated entity, and establishes a private right of action for women to seek damages, including statutory and punitive, against non-compliant providers. The bill explicitly states that it does not preempt state laws that establish more extensive disclosure requirements or penalties.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Introduced in House
Referred to the House Committee on Energy and Commerce.
Health
Chemical Abortion Risk Awareness Act
USA119th CongressHR-7237| House
| Updated: 1/23/2026
This bill proposes to amend the Public Health Service Act by adding a new title focused on "Chemical Abortion Risk Awareness." It defines "chemical abortion" as the use of abortion-inducing drugs to cause the death of an unborn child, specifically excluding treatments for ectopic or molar pregnancies and miscarriages. The legislation applies to any chemical abortion provider who receives federal funds or works for an entity that does, aiming to ensure women are comprehensively informed about the procedure's risks. Under the bill, these providers must, at least 24 hours before a chemical abortion, provide the woman with both electronic and paper copies of the full FDA-approved product label for each drug, with "Warnings and Precautions" sections highlighted. They are also required to read these highlighted sections aloud to the woman and obtain her written confirmation that these steps were completed. Failure to comply can result in the Secretary withholding federal funding from the provider or their associated entity, and establishes a private right of action for women to seek damages, including statutory and punitive, against non-compliant providers. The bill explicitly states that it does not preempt state laws that establish more extensive disclosure requirements or penalties.